Price: $107.79, Change: $+0.08, Percent Change: +0.07%
Related Articles
Wire
Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application
Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.
$SVRA
Wire
Euroseas Extends EM Kea Charter for Three Years at Higher Daily Rate
Euroseas (ESEA) extended a charter contract for its feeder containership EM Kea by three years at a gross daily rate of $30,000.The charter is set to begin on July 14 and reflects nearly a 60% increase over the vessel's current rate, the company said Wednesday in a statement.Euroseas expects the charter to generate about $22.5 million in EBITDA over the minimum contracted period.The company's shares fell 2% in after-hours trading.
$ESEA
Wire
Voyager Wins NASA Order for Seventh Private Astronaut Mission to International Space Station
Voyager Technologies (VOYG) said late Wednesday it has signed an order with National Aeronautics and Space Administration for the seventh private astronaut mission to the International Space Station, with a launch planned no earlier than 2028.The mission, dubbed VOYG-1, supports NASA's strategy to shift low-Earth orbit operations to the private sector by enabling commercial partners to deliver human spaceflight services, the company said.
$VOYG